A Study to Evaluate the Safety and Efficacy of CR845 in Chronic Kidney Disease Patients With Moderate-to-Severe Pruritus
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 269 participants.
Also called NCT03617536
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 269 participants
- Sponsor
- Registry
-
NCT03617536
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT03617536. Randomized; double masking; primary purpose treatment. Start 2018-07-05 (actual); primary completion 2019-10-24 (actual). Results posted on 2024-01-24.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Evaluate the Safety and Efficacy of CR845 in Chronic Kidney Disease Patients With Moderate-to-Severe Pruritus
- Condition
- Chronic Kidney Diseases
- Condition
- Pruritus
- Intervention (Drug)
- CR845 0.25 mg Oral Tablet
- Intervention (Drug)
- CR845 0.5 mg Oral Tablet
- Intervention (Drug)
- CR845 1 mg Oral Tablet
- Intervention (Drug)
- Placebo Oral Tablet
- Lead sponsor
- Cara Therapeutics, Inc.
Record details
- Record id
cardio:ct-nct03617536- Content hash
3d13ce7961f697f34b81fe79ae9466a09d2d0a2ce3c8c69733d6350badfea2d5